CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury. / Ashina, Håkan; Iljazi, Afrim; Al-Khazali, Haidar M.; Do, Thien Phu; Eigenbrodt, Anna K.; Larsen, Eigil L.; Andersen, Amalie M.; Hansen, Kevin J.; Bräuner, Karoline B.; Chaudhry, Basit Ali; Christensen, Casper E.; Amin, Faisal Mohammad; Schytz, Henrik W.
I: Journal of Headache and Pain, Bind 23, Nr. 1, 135, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury
AU - Ashina, Håkan
AU - Iljazi, Afrim
AU - Al-Khazali, Haidar M.
AU - Do, Thien Phu
AU - Eigenbrodt, Anna K.
AU - Larsen, Eigil L.
AU - Andersen, Amalie M.
AU - Hansen, Kevin J.
AU - Bräuner, Karoline B.
AU - Chaudhry, Basit Ali
AU - Christensen, Casper E.
AU - Amin, Faisal Mohammad
AU - Schytz, Henrik W.
N1 - Publisher Copyright: © 2022, The Author(s).
PY - 2022
Y1 - 2022
N2 - Objective: To ascertain whether intravenous infusion of calcitonin gene-related peptide (CGRP) can induce migraine-like headache in people with persistent post-traumatic headache attributed to mild traumatic brain injury (TBI) and no pre-existing migraine. Methods: A non-randomized, single-arm, open-label study at a single site in Denmark. Eligible participants were aged 18 to 65 years and had a known history of persistent post-traumatic headache attributed to mild TBI for ≥ 12 months. All participants received continuous intravenous infusion of CGRP (1.5 µg/min) over 20 min. A headache diary was used to collect outcome data until 12 h after the start of CGRP infusion. The primary end point was the incidence of migraine-like headache during 12-hour observational period. Results: A total of 60 participants completed the study protocol and provided data for the analysis of the primary end point. The median age was 32.5 (IQR, 25.5–43.0) years; 43 participants (72%) were female. Following CGRP infusion, 43 (72%) of 60 participants developed migraine-like headache during the 12-hour observational period. The median time to peak headache intensity was 40 min (IQR, 20–60), and the median peak headache intensity was 6 (IQR, 5–8) on the 11-point numeric rating scale. Conclusion: Intravenous infusion of CGRP is a potent inducer of migraine-like headache in people with persistent post-traumatic headache attributed to mild TBI. This observation underscores the importance of CGRP in the genesis of migraine-like headache that is often experienced by individuals who are afflicted by persistent post-traumatic headache. Further research is warranted to ascertain whether other signaling molecules also contribute to the disease mechanisms underlying post-traumatic headache.
AB - Objective: To ascertain whether intravenous infusion of calcitonin gene-related peptide (CGRP) can induce migraine-like headache in people with persistent post-traumatic headache attributed to mild traumatic brain injury (TBI) and no pre-existing migraine. Methods: A non-randomized, single-arm, open-label study at a single site in Denmark. Eligible participants were aged 18 to 65 years and had a known history of persistent post-traumatic headache attributed to mild TBI for ≥ 12 months. All participants received continuous intravenous infusion of CGRP (1.5 µg/min) over 20 min. A headache diary was used to collect outcome data until 12 h after the start of CGRP infusion. The primary end point was the incidence of migraine-like headache during 12-hour observational period. Results: A total of 60 participants completed the study protocol and provided data for the analysis of the primary end point. The median age was 32.5 (IQR, 25.5–43.0) years; 43 participants (72%) were female. Following CGRP infusion, 43 (72%) of 60 participants developed migraine-like headache during the 12-hour observational period. The median time to peak headache intensity was 40 min (IQR, 20–60), and the median peak headache intensity was 6 (IQR, 5–8) on the 11-point numeric rating scale. Conclusion: Intravenous infusion of CGRP is a potent inducer of migraine-like headache in people with persistent post-traumatic headache attributed to mild TBI. This observation underscores the importance of CGRP in the genesis of migraine-like headache that is often experienced by individuals who are afflicted by persistent post-traumatic headache. Further research is warranted to ascertain whether other signaling molecules also contribute to the disease mechanisms underlying post-traumatic headache.
KW - CGRP
KW - Concussion
KW - Migraine
KW - Pathophysiology
KW - Trigeminovascular System
UR - http://www.scopus.com/inward/record.url?scp=85140029380&partnerID=8YFLogxK
U2 - 10.1186/s10194-022-01499-5
DO - 10.1186/s10194-022-01499-5
M3 - Journal article
C2 - 36253732
AN - SCOPUS:85140029380
VL - 23
JO - Journal of Headache and Pain
JF - Journal of Headache and Pain
SN - 1129-2369
IS - 1
M1 - 135
ER -
ID: 329248761